Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 142 views

    Kyle Li

    Uploaded by

    api-407846283
    Kyle was born in 1987 in Florida and was diagnosed with osteosarcoma, the most common bone cancer in teenagers, at age 14. Milk Be Gone (MBG) is a monoclonal antibody designed to promote bone growth and tag osteosarcoma cells so the immune system can destroy them. This clinical trial will evaluate the use of intravenous MBG monoclonal antibodies in male teenagers aged 13-17 with localized osteosarcoma in the lower extremities to trigger cancer cell death through apoptosis in a safe, controlled, randomized, and double-blind manner.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd

    Kyle Li

    Uploaded by

    api-407846283
    142 views12 pages
    Kyle was born in 1987 in Florida and was diagnosed with osteosarcoma, the most common bone cancer in teenagers, at age 14. Milk Be Gone (MBG) is a monoclonal antibody designed to promote bone growth and tag osteosarcoma cells so the immune system can destroy them. This clinical trial will evaluate the use of intravenous MBG monoclonal antibodies in male teenagers aged 13-17 with localized osteosarcoma in the lower extremities to trigger cancer cell death through apoptosis in a safe, controlled, randomized, and double-blind manner.

    Original Title

    kyle li

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Kyle was born in 1987 in Florida and was diagnosed with osteosarcoma, the most common bone cancer in teenagers, at age 14. Milk Be Gone (MBG) is a monoclonal antibody designed to promote bone growth and tag osteosarcoma cells so the immune system can destroy them. This clinical trial will evaluate the use of intravenous MBG monoclonal antibodies in male teenagers aged 13-17 with localized osteosarcoma in the lower extremities to trigger cancer cell death through apoptosis in a safe, controlled, randomized, and double-blind manner.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    142 views12 pages

    Kyle Li

    Uploaded by

    api-407846283
    Kyle was born in 1987 in Florida and was diagnosed with osteosarcoma, the most common bone cancer in teenagers, at age 14. Milk Be Gone (MBG) is a monoclonal antibody designed to promote bone growth and tag osteosarcoma cells so the immune system can destroy them. This clinical trial will evaluate the use of intravenous MBG monoclonal antibodies in male teenagers aged 13-17 with localized osteosarcoma in the lower extremities to trigger cancer cell death through apoptosis in a safe, controlled, randomized, and double-blind manner.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 12

    Kyle Hi

    Alison Stefansic and Kayla Pintro


    All about Kyle...
    Kyle was born in 1987 in Tallahassee, Florida, to Chinese parents. Kyle was a
    very active teenager who loved music. At 14, Kyle began to feel pain in his knee
    joint and started developing a limp. Soon after the onset of this pain, Kyle began
    feeling tired and started to lose weight. Kyle was soon diagnosed with
    Osteosarcoma, the most common bone cancer in children and teenagers. Kyle
    was treated with chemotherapy and surgery. There was no history of cancer in
    Kyle’s family. Kyle’s cancer had not spread to other parts of the body, and the
    surgery removed all of the cancerous cells. Kyle is now 21 and is in his junior year
    at Florida State University.
    Milk Be Gone (MGB)
    Milk Be Gone (MBG) is a specifically designed monoclonal
    antibody which is designed for osteosarcoma patients.
    Scientists designed this mAb to promote bone growth due to
    its properties which tag cancer cells so the body can know
    where apoptosis needs to take place. This is through (MBG)
    monoclonal antibody which attaches itself on the antibody
    which then when inserted into the body can attach to
    antigens and flag the cell.
    Administration and Target Cell Delivery

    (MBG) is administered intravenously Because antibodies are large proteins,


    through a vein. They circulate in the blood they can not pass through cellular
    and other bodily fluids defending against membranes. Instead they attach on the
    bacteria and viruses searching outside of these membranes to bind to
    specifically for osteosarcoma cells. The the antigen cancerous cells.
    binding of the MBG antibody to the
    antigen triggers an immune response to
    engulf and destroy the antigens. However,
    may be combined with other
    chemotherapy treatments to fight cancer.
    Intracellular Treatment and Destruction

    The (MBG) mAb does not ever enter the cell it Through the blockage of pathways with specific
    inhibits a complex series of events inside the cell antibodies known as immune checkpoint
    which causes it to self destruct. Chemotherapy inhibitors, the immune system response
    treatment is then proceeded (typically radiation). destroys these targeted cells through apoptosis.

    Cancer cells create large amounts of growth


    factor receptors which sit on the cell and
    signals for cell division and survival.
    Unique and Better Advancements

    This technology is better than current Monoclonal antibodies have been around
    treatments because since osteosarcoma is since the 1960’s however the first
    in Kyle’s lower body many current treatments licensed mAb was in 1986 for kidney
    require surgery for amputation or cancer transplant rejection prevention. There are
    removal which can be life threatening. This multiple types of mAb’s which are widely
    less invasive approach to intracellular cancer
    used for treatments according to the
    elimination is more cost effective and more
    problem which makes it very unique to the
    accurate as it targets every cancerous cell.
    patient.
    The minimally invasive techniques of
    administration through injection provides a
    safer alternative to surgery and
    chemotherapy.
    The Use of (MBG) in Youth in
    Osteosarcoma
    This trial will focus on the use of the monoclonal antibody
    used in MBG to see if it can produce bone growth and tag the
    proper cancerous cells to trigger apoptosis and cancerous
    cell death. It will use an intravenous injection of MBG
    monoclonal antibodies to effectively travel and target
    osteosarcoma cancer cells in an effort to trigger cancerous
    cell death in lower extremity bone cancer.
    The Use of (MBG) in Youth in Osteosarcoma

    Criteria for population:


    The primary population
    being studied male youth ●
    ●
    Male
    Between the ages of 13-17
    between the ages of 13-17 ● Been diagnosed with osteosarcoma
    ● Cancer located in lower extremities (legs)
    with Osteosarcoma in the ● Has not spread to further areas (localized)
    ● Has not had previous surgery to attempt
    lower extremities. to remove cancer
    ● Not involved in any other clinical trial
    The Use of (MBG) in Youth in Osteosarcoma
    Safety procedure:
    Risks:
    1. Lab cleaning crew will sterilize
    ● New procedure
    laboratory area
    ● Contamination if needle is not
    2. Qualified Scientist will wash
    sterile for patient and scientist
    hands then put on gloves.
    ● Scientist exposed to biological
    3. A laboratory nurse with sterilize
    proteins
    injection needle and patient arm.
    ● With future applications, the
    4. Qualified Scientist will inject
    MBG monoclonal antibodies
    monoclonal antibodies into the
    could trigger the apoptosis of
    vein and then dispose of syringe
    non-cancerous cells
    and needle into waste basket.
    Trial Type: Controlled, Randomized,
    Double-Blind Trial
    The Use of Control: Control group is given standard

    (MBG) in Youth chemotherapy to kill of cancerous cells

    in Independent Variable: monoclonal


    antibodies

    Osteosarcoma Dependent Variable: cancer cell


    population after MBG treatment

    Hypothesis: If the MGB monoclonal


    antibodies can effectively connect to the
    cancerous cells then apoptosis will occur
    because the antibody would have flagged
    the cancerous cells.
    References
    Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: successes,
    limitations and hopes for the future. British Journal of Pharmacology, 157(2), 220-233.
    doi:10.1111/j.1476-5381.2009.00190.x

    G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide
    DLVPR with high affinity. (n.d.). Retrieved from
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339894/

    Monoclonal antibodies to treat cancer. (n.d.). Retrieved from


    https://www.cancer.org/treatment/treatments-and-side-effects/treatment-
    types/immunotherapy/monoclonal-antibodies.html

    What Are Clinical Trials and Studies? (n.d.). Retrieved from https://www.nia.nih.gov/health/what-are-
    clinical-trials-and-studies
    Questions?

    You might also like